•  
  •  
 

Central Asian Journal of Medicine

Abstract

Introduction The literature provides data on extrahepatic manifestations of the hepatitis C virus (HCV), its possible direct or immuno-mediated effects on pancreatic β-cells and its role in the etiology and pathogenesis of diabetes. There are also reports of a high prevalence of HCV in type 2 diabetes mellitus.Purpose of study to evaluate the clinical significance of insulin resistance on indicators of carbohydrate-lipid metabolism in patients with chronic hepatitis C. Material and methods. The study included 41 patients with chronic hepatitis C, who examined in the clinic Republican specialized scientific-practical medical centre of virology.The diagnosis of chronic hepatitis C was made on the basis of detection of virus markers in the blood: HCV-Ab, RNA-HCV by the method of passive agglutination of gelatinous particles (Serodia, Japan) and polymerase chain reaction (PCR), as well as by the combination of clinical and medical history, epidemiological, biochemical, instrumental data, according to the classification of chronic hepatitis. Results In the vast majority (68.2%) of patients, hepatitis C was detected during screening and only 1/3 of the patients were examined purposefully due to the presence of clinical and laboratory abnormalities. In almost half of the patients (47.6%), the duration of hepatitis was more than 8 years, in 28.6% from 3 to 8 years, 14.9 to 3 years, and in 8.9% the duration of the disease could not be established. 75.6% of patients had minimal clinical manifestation of hepatitis. Conclusion Insulin resistance was detected in 31.7% of patients with chronic hepatitis C and characterized by the severity of the clinical picture with a predominance of asthenic syndrome, enlargement and densification of the liver compared with patients without IR insulin resistance. In 2/3 of patients with chronic hepatitis C with insulin resistance, abdominal obesity and a decrease in high-density lipoprotein cholesterol were found, which is significantly more often compared to patients without insulin resistance.

First Page

179

Last Page

187

References

1. Abdukadyrova M.A., Abduzhalilova N.A., Kuziyahmetova I.YU. Prognosticheskoe znachenie immunogeneticheskih faktorov u bol'nyh virusnym gepatitom S // Allergiya, astma i klinicheskaya immunologiya. -1999.-№12.-S.24-26. 2. Antonova T.V., Romanova M.A., Sergeeva E.G. Hronicheskij gepatit S u bol'nyh s metabolicheskim sindromom //ZHurnal infektologii. – 2011. – T. 3, № 3. - S. 91-96. 3. Alieva A.V., Rahimova G.N., Ismailov S.I. Epidemiologiya saharnogo diabeta i prediabeta v Uzbekistane: rezul'taty skrininga // ZHurnal klinicheskoj i teoreticheskoj klinicheskoj mediciny. -2017.-№ 2 C.58-61 4. Bajzhanova, ZH.ZH. Metabolicheskij sindrom u pacientov s hronicheskim gepatitom S // Klin. gepatologiya.- 2010. - №1.- S.17-23. 5. Bogomolov, P.O. Nealkogol'naya zhirovaya bolezn' pecheni: steatozi nealkogol'nyj steatogepatit. Klin. perspektivy gastroenterologii, gepatologii. - 2004.- №3. - S.20-27. 6. Gulinskaya, O.V. CyrkunovV.M. Insulinorezistentnost' u pacientov s hronicheskim gepatitom S. //Sovremennye problemy infekcionnoj patologii cheloveka -Minsk.- 2012.- S.175-178. 7. Dedov I.I., Mel'nichenko G.A., Fadeev V.V. / Endokrinologiya. – M: Medicina, 2000. - S.631-638. 8. Zel'cer M.E. Insulinoterapiya bol'nyh saharnym diabetom 2 tipa: / Metod.rekomendacii. - Almaty, 2002. – C18-20. 9. Ignatova, T. M.,AprosinaZ.G., SerovV.V. Vnepechenochnye proyavleniya hronicheskoj HCV-infekcii//Ros.med. zhurnal.- 2001.- №2.- S.13-18. 10. Musabaev I.K., Musabaev E.I. Differencial'naya diagnostika gepatitov A, V, S, D, E, G.- Tashkent,1999.-C 86-89. 11. Musabaev E.I. Kan M.V., Mustafaeva E., Bondarenko I. G.. Virusnyj gepatit S i ego rol' v patologii pecheni Hronicheskiezabolevaniya pecheni- ot virusnogo gepatita do cirroza s portal'noj gipertenziej.– Tashkent,1996.- S. 28-29. 12. Priven V.Z., Pogorelov M.E. Klinicheskaya harakteristikaepidemicheskogo gepatita u bol'nyh saharnym diabetom // Ostryjvirusnyj gepatit i ego posledstviya: Voprosy epidemiologii,patogeneza, kliniki i profilaktiki.-Habarovsk,-1996- S.92-97 13. Rahimova G.N. Standarty po vedeniyu i lecheniyu saharnogo diabeta 2 tipa (rukovodstvo dlya vrachej) Tashkent - 2018 - Str 4-5 14. Romanova M.A., Antonova T.V., Sergeeva E.G. Pokazatel' indeksa HOMA-IR u bol'nyh hronicheskim gepatitom S //Uchenye zapiski SPbGMU im. akademika I.P.Pavlova. – 2010. – Tom XVII, №4. – S.44-46. 15. Stel'mah, V. V.,RadchenkoV.G.,KozlovV.K. Racional'naya terapiya hronicheskogo gepatita C. Vrach. - 2006. - №2.- S.57-62. 16. Hafisova O.O. [i dr.] Vliyanie Metformina na formirovanie ustojchivogo virusologicheskogo otveta.Vestnik RUDN.- 2011.- №2.- S.48-57 17. SHagazatova B.H. Saharnyj diabet: Sostoyanie mediko-social'noj pomoshchi i sovershenstvovanie osnov lechebno-profilakticheskoj pomoshchi: Avtoref. diss. na soisk. uch. step. dokt.med.nauk.-T.,2004.-29s. 18. DiabetesAtlas // IDF -2017- P.5-10 19. Bortoletto, G. Insulin resistance (IR) defined by the homeostasis model of assessment insulin resistance (HOMA-IR) index has a direct effect on early viral kinetics during pegylated-interferon therapy for chronic hepatitis C. // Hepatology.- 2007.- Vol.46.- Р.361. 20. СаmmaС. [et al.] Insulin resistance is associated with steatosis in non-diabeticpatients with genotype 1 chronic hepatitis Hepatology. - 2006. - Vol.43. - Р.64-71. 21. Harrison, S.A. Correlation between insulin resistance and hepatitis C viral load. // Hepatology. - 2006. - Vol.43. - Р.1168. 22. Huang [et al.] Hepatitis C viremia increases the association with type 2diabetes mellitus in a hepatitis B and C endemic area: an epidemiological link with virologicalimplication.J. Gastroenterol. - 2007. - Vol.102. - Р.1237-1243. 23. Hui, J.M. Insulin resistance is associated with chronic hepatitis C and virus infection fibrosis progression.// Gastroenterology. - 2003. - Vol.125. - Р.1695-1704. 24. Hadziyannis [et al.]Peginterferon alfa-2a and ribavirin combination therapyinchronic hepatitis C. A randomized study of treatment duration and ribavirin dose Ann. Intern. Med. - 2004. -Vol.140. - P.346 -355. 25. RomeroGomez M. [et al.]Insulin resistance impairs sustained response ratetopeginterferon plus ribavirin in chronic hepatitis C patients// Gastroenterology.-2006.-Vol.128.-№3.-Р.636-641. 26. Kawaguchi, T. Causal relationship between hepatitis C virus core and the development of type 2 diabetes mellitus in a hepatitis C virus hyperendemic area: a pilot study.// Int. J. Mol. Med. - 2005. - Vol.16. - Р.109-114. 27. Khalili M., Lim J.W., Bass N. et al. New onset diabetes mellitus after liver transplantation: the critical role of hepatitis C infection. / Liver Transplant. - 2004. - №10. - Р.349-355. 28. Mehta, S.H. Hepatitis C virus infection and incident type 2 diabet. // Hepatology. -2003. - Vol.38. - Р.50-56. 29. Petit, J-M. Risk factors for diabetes mellitus and early insulin resistance in chronic hepatitis C.// J. Hepatol. - 2001. - Vol.35. - Р.279-283. 30. Siagris D., Vafíadis G., Michalaki M. et al Serum adiponectin in chronic hepatitis C and B //J Viral Hepat. 2007. - Vol. 14, № 8. - P. 577-583. 31. Souza A.F., Pace F.H., Chebli J.M., Ferreira L.E. Insulin resistance in non-diabetic patients with chronic hepatitis C: what does it mean? //Arq Bras Endocrinol Metabol. -2011. Vol. 55, №6. P. 412-418. 32. Tachi Y., Katano Y., Honda T. Impact of amino acid substitutions in the hepatitis C virus genotype lb core region on liver steatosis and hepatic oxidative stress in patients with chronic hepatitis C. //Liver Int. 2010. - Vol. 30, №4.-P. 554-559.

Share

COinS
 
 

To view the content in your browser, please download Adobe Reader or, alternately,
you may Download the file to your hard drive.

NOTE: The latest versions of Adobe Reader do not support viewing PDF files within Firefox on Mac OS and if you are using a modern (Intel) Mac, there is no official plugin for viewing PDF files within the browser window.